[Molecular profiling and predictive signatures. Biomarker analysis in ovarian cancer].
The identification of tissue-based biomarkers is a major task for molecular cancer research. As ovarian cancer is a malignancy with a particular poor prognosis, new diagnostic tests are needed for the planning of an individualized therapy. Diagnostic biomarkers are investigated on different biological levels using genomics, transcriptomics, proteomics or metabolomics as a major approach. Protein biomarkers as well as RNA biomarkers can be measured in formalin-fixed tissue using immunohistochemistry as well as new techniques for isolation of nucleic acids. Furthermore, gene expression as well as metabolic signatures can be determined using frozen tissue. In a first evaluation, metabolomics has been used to investigate different types of ovarian tumors. In a systems pathology approach the results from the different biological levels are integrated to a combined signature that reflects the biological behaviour of the tumor.
Denkert
C
C
Institut für Pathologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin. carsten.denkert@charite.de
D014408:Biomarkers, Tumor / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D055432:Metabolomics / Q000379:methods; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D010053:Ovary / Q000473:pathology; D011379:Prognosis; D040901:Proteomics; D012334:RNA, Neoplasm / Q000235:genetics
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm